JP6832616B2 - Liquid oral composition - Google Patents
Liquid oral composition Download PDFInfo
- Publication number
- JP6832616B2 JP6832616B2 JP2015064356A JP2015064356A JP6832616B2 JP 6832616 B2 JP6832616 B2 JP 6832616B2 JP 2015064356 A JP2015064356 A JP 2015064356A JP 2015064356 A JP2015064356 A JP 2015064356A JP 6832616 B2 JP6832616 B2 JP 6832616B2
- Authority
- JP
- Japan
- Prior art keywords
- allantoin
- oral composition
- liquid oral
- extract
- liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000007788 liquid Substances 0.000 title claims description 112
- 239000000203 mixture Substances 0.000 title claims description 101
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 154
- 229960000458 allantoin Drugs 0.000 claims description 76
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 75
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 67
- 210000000214 mouth Anatomy 0.000 claims description 33
- 230000014759 maintenance of location Effects 0.000 claims description 31
- 239000000551 dentifrice Substances 0.000 claims description 29
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 29
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 29
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- -1 chlorohydroxyaluminum Chemical compound 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 17
- 238000002156 mixing Methods 0.000 claims description 14
- 239000000284 extract Substances 0.000 claims description 12
- 230000000087 stabilizing effect Effects 0.000 claims description 8
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 4
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 4
- 244000228451 Stevia rebaudiana Species 0.000 claims description 4
- 239000004359 castor oil Substances 0.000 claims description 4
- 235000019438 castor oil Nutrition 0.000 claims description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 4
- 229940041616 menthol Drugs 0.000 claims description 4
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 claims description 4
- 241000207199 Citrus Species 0.000 claims description 3
- 235000020971 citrus fruits Nutrition 0.000 claims description 3
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims 6
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims 6
- RKFMOTBTFHXWCM-UHFFFAOYSA-M [AlH2]O Chemical compound [AlH2]O RKFMOTBTFHXWCM-UHFFFAOYSA-M 0.000 claims 4
- 244000166124 Eucalyptus globulus Species 0.000 claims 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims 3
- 235000012733 azorubine Nutrition 0.000 claims 3
- 229940119217 chamomile extract Drugs 0.000 claims 3
- 235000020221 chamomile extract Nutrition 0.000 claims 3
- YSVBPNGJESBVRM-UHFFFAOYSA-L disodium;4-[(1-oxido-4-sulfonaphthalen-2-yl)diazenyl]naphthalene-1-sulfonate Chemical compound [Na+].[Na+].C1=CC=C2C(N=NC3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)O)=CC=C(S([O-])(=O)=O)C2=C1 YSVBPNGJESBVRM-UHFFFAOYSA-L 0.000 claims 3
- 229960005191 ferric oxide Drugs 0.000 claims 3
- 235000013980 iron oxide Nutrition 0.000 claims 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims 3
- 229960002216 methylparaben Drugs 0.000 claims 3
- GMMAPXRGRVJYJY-UHFFFAOYSA-J tetrasodium 4-acetamido-5-hydroxy-6-[[7-sulfonato-4-[(4-sulfonatophenyl)diazenyl]naphthalen-1-yl]diazenyl]naphthalene-1,7-disulfonate Chemical compound [Na+].[Na+].[Na+].[Na+].OC1=C2C(NC(=O)C)=CC=C(S([O-])(=O)=O)C2=CC(S([O-])(=O)=O)=C1N=NC(C1=CC(=CC=C11)S([O-])(=O)=O)=CC=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 GMMAPXRGRVJYJY-UHFFFAOYSA-J 0.000 claims 3
- LVYZJEPLMYTTGH-UHFFFAOYSA-H dialuminum chloride pentahydroxide dihydrate Chemical compound [Cl-].[Al+3].[OH-].[OH-].[Al+3].[OH-].[OH-].[OH-].O.O LVYZJEPLMYTTGH-UHFFFAOYSA-H 0.000 claims 2
- 235000020737 peppermint extract Nutrition 0.000 claims 2
- 241001125046 Sardina pilchardus Species 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 235000019512 sardine Nutrition 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 29
- 238000003860 storage Methods 0.000 description 17
- 238000009472 formulation Methods 0.000 description 12
- 238000011156 evaluation Methods 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- 239000002324 mouth wash Substances 0.000 description 10
- 235000014113 dietary fatty acids Nutrition 0.000 description 9
- 239000000194 fatty acid Substances 0.000 description 9
- 229930195729 fatty acid Natural products 0.000 description 9
- 229940051866 mouthwash Drugs 0.000 description 8
- 235000010443 alginic acid Nutrition 0.000 description 7
- 229920000615 alginic acid Polymers 0.000 description 7
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 6
- 229940072056 alginate Drugs 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
- 239000003205 fragrance Substances 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000002562 thickening agent Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 238000007599 discharging Methods 0.000 description 4
- 230000009610 hypersensitivity Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 102000000340 Glucosyltransferases Human genes 0.000 description 3
- 108010055629 Glucosyltransferases Proteins 0.000 description 3
- 241000219925 Oenothera Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002125 Sokalan® Chemical class 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 208000006558 Dental Calculus Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 235000004496 Oenothera biennis Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000767 anti-ulcer Effects 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 2
- 229960001950 benzethonium chloride Drugs 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000004268 dentin Anatomy 0.000 description 2
- 239000002781 deodorant agent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 238000000569 multi-angle light scattering Methods 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000004584 polyacrylic acid Chemical class 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000000395 remineralizing effect Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 240000005528 Arctium lappa Species 0.000 description 1
- 235000003130 Arctium lappa Nutrition 0.000 description 1
- 235000008078 Arctium minus Nutrition 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- MHUNPSARLCGSPP-UHFFFAOYSA-N CC.OP(=O)OP(O)(O)=O Chemical class CC.OP(=O)OP(O)(O)=O MHUNPSARLCGSPP-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 108010001682 Dextranase Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Chemical class 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical class CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 241001071795 Gentiana Species 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- 241000245063 Primula Species 0.000 description 1
- 235000016311 Primula vulgaris Nutrition 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 241000533293 Sesbania emerus Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- 240000004584 Tamarindus indica Species 0.000 description 1
- 235000004298 Tamarindus indica Nutrition 0.000 description 1
- XOAAWQZATWQOTB-UHFFFAOYSA-N Taurine Natural products NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- SLINHMUFWFWBMU-UHFFFAOYSA-N Triisopropanolamine Chemical compound CC(O)CN(CC(C)O)CC(C)O SLINHMUFWFWBMU-UHFFFAOYSA-N 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- XPCTZQVDEJYUGT-UHFFFAOYSA-N allomaltol Natural products CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 235000010407 ammonium alginate Nutrition 0.000 description 1
- 239000000728 ammonium alginate Substances 0.000 description 1
- KPGABFJTMYCRHJ-YZOKENDUSA-N ammonium alginate Chemical compound [NH4+].[NH4+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O KPGABFJTMYCRHJ-YZOKENDUSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 229940069765 bean extract Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001559 benzoic acids Chemical class 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920003174 cellulose-based polymer Polymers 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- HWDGVJUIHRPKFR-UHFFFAOYSA-I copper;trisodium;18-(2-carboxylatoethyl)-20-(carboxylatomethyl)-12-ethenyl-7-ethyl-3,8,13,17-tetramethyl-17,18-dihydroporphyrin-21,23-diide-2-carboxylate Chemical compound [Na+].[Na+].[Na+].[Cu+2].N1=C(C(CC([O-])=O)=C2C(C(C)C(C=C3C(=C(C=C)C(=C4)[N-]3)C)=N2)CCC([O-])=O)C(=C([O-])[O-])C(C)=C1C=C1C(CC)=C(C)C4=N1 HWDGVJUIHRPKFR-UHFFFAOYSA-I 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 1
- DDXLVDQZPFLQMZ-UHFFFAOYSA-M dodecyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)C DDXLVDQZPFLQMZ-UHFFFAOYSA-M 0.000 description 1
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 229920001249 ethyl cellulose Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 108010000165 exo-1,3-alpha-glucanase Proteins 0.000 description 1
- 239000010643 fennel seed oil Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940074774 glycyrrhizinate Drugs 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 229940039371 karaya gum Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229940043353 maltol Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229930007503 menthone Natural products 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- JACMPVXHEARCBO-UHFFFAOYSA-N n-pentylpentan-1-amine Chemical compound CCCCCNCCCCC JACMPVXHEARCBO-UHFFFAOYSA-N 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- HLERILKGMXJNBU-UHFFFAOYSA-N norvaline betaine Chemical compound CCCC(C([O-])=O)[N+](C)(C)C HLERILKGMXJNBU-UHFFFAOYSA-N 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000010408 potassium alginate Nutrition 0.000 description 1
- 239000000737 potassium alginate Substances 0.000 description 1
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003870 salicylic acids Chemical class 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 229940079841 sodium copper chlorophyllin Drugs 0.000 description 1
- 235000013758 sodium copper chlorophyllin Nutrition 0.000 description 1
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- BFDWBSRJQZPEEB-UHFFFAOYSA-L sodium fluorophosphate Chemical compound [Na+].[Na+].[O-]P([O-])(F)=O BFDWBSRJQZPEEB-UHFFFAOYSA-L 0.000 description 1
- 229940075560 sodium lauryl sulfoacetate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229950005425 sodium myristyl sulfate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 150000003398 sorbic acids Chemical class 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- ANOBYBYXJXCGBS-UHFFFAOYSA-L stannous fluoride Chemical compound F[Sn]F ANOBYBYXJXCGBS-UHFFFAOYSA-L 0.000 description 1
- 229960002799 stannous fluoride Drugs 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 229910001631 strontium chloride Inorganic materials 0.000 description 1
- AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000001040 synthetic pigment Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 239000011746 zinc citrate Substances 0.000 description 1
- 235000006076 zinc citrate Nutrition 0.000 description 1
- 229940068475 zinc citrate Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本発明は、アラントイン及び/又はその誘導体の安定性が向上しており、保存安定性に優れ、しかも口腔内でのべたつきが抑制されていながら滞留性が向上している液状口腔用組成物に関する。 The present invention relates to a liquid oral composition in which the stability of allantoin and / or its derivative is improved, the storage stability is excellent, and the retention is improved while the stickiness in the oral cavity is suppressed.
アラントイン及びその誘導体には、抗炎症作用、細胞賦活作用、止血作用、殺菌作用、抗潰瘍作用等があり、口腔用組成物に使用されている。しかしながら、アラントイン及びその誘導体は、水との共存下で分解が生じ易く、液状口腔用組成物に配合すると保存安定性が劣るという欠点が知られている(例えば、非特許文献1参照)。 Allantoin and its derivatives have anti-inflammatory action, cell activation action, hemostatic action, bactericidal action, anti-ulcer action and the like, and are used in oral compositions. However, it is known that allantoin and its derivatives are easily decomposed in the coexistence with water and have inferior storage stability when blended in a liquid oral composition (see, for example, Non-Patent Document 1).
そこで、従来、液状口腔用組成物において、アラントイン及び/又はその誘導体の安定性を向上させる製剤技術が種々検討されている。例えば、特許文献1には、(A)イソプロピルメチルフェノール、(B)アラントイン、(C)エチレンオキサイドの平均付加モル数が40〜100モルのポリオキシエチレン硬化ヒマシ油、並びに(D)クエン酸とクエン酸塩もしくはクエン酸塩以外のアルカリ剤、又はクエン酸塩とクエン酸もしくはクエン酸以外の酸とを組合せたものを、所定量配合した液体口腔用組成物が、アラントインの加水分解を抑制し得ることが開示されている。また、特許文献2には、(A)アラントイン又はその塩、(B)乳酸及びそのアルカリ金属塩、並びに(C)水を所定量配合し、且つpHを4.5〜6に調整した透明液体口腔用組成物によっても、アラントインの加水分解を抑制し得ることが開示されている。更に、従来、水との共存下でのアラントイン及びその誘導体の分解は、エタノール等の低級アルコールの配合によっても、ある程度は抑制し得ることが知られている。 Therefore, conventionally, various preparation techniques for improving the stability of allantoin and / or its derivatives have been studied in liquid oral compositions. For example, Patent Document 1 describes (A) isopropylmethylphenol, (B) allantin, (C) polyoxyethylene hydrogenated castor oil having an average addition molar number of 40 to 100 mol, and (D) citric acid. A liquid oral composition containing a predetermined amount of citric acid or an alkaline agent other than citrate, or a combination of citric acid and citric acid or an acid other than citric acid suppresses the hydrolysis of allantin. It is disclosed to get. Further, Patent Document 2 contains (A) allantin or a salt thereof, (B) lactic acid and an alkali metal salt thereof, and (C) a transparent liquid in which a predetermined amount of water is blended and the pH is adjusted to 4.5 to 6. It is disclosed that the oral composition can also suppress the hydrolysis of allantin. Further, conventionally, it is known that the decomposition of allantoin and its derivatives in the coexistence with water can be suppressed to some extent by blending a lower alcohol such as ethanol.
しかしながら、液状口腔用組成物において、アラントイン及び/又はその誘導体の安定化を図る従来の製剤技術では、処方に制約があるため、近年の多様化する液状口腔用組成物の処方に対応できないケースがある。 However, in the liquid oral composition, there are cases where the conventional formulation technology for stabilizing allantoin and / or its derivative cannot cope with the diversifying formulation of the liquid oral composition in recent years due to the limitation of the formulation. is there.
更に、液状口腔用組成物において、アラントイン及び/又はその誘導体の薬効を効果的に発揮させる上で、口腔内での滞留性が優れていることが重要になる。従来、液状口腔用組成物の口腔内での滞留性は、増粘剤の配合によって向上させ得ることが知られている。しかしながら、増粘剤の配合による滞留性の向上は、通常はべたつきを伴うため、使用感が低下するという欠点がある。 Further, in the liquid oral composition, it is important that the allantoin and / or its derivative has excellent retention in the oral cavity in order to effectively exert the medicinal effect. Conventionally, it is known that the retention of a liquid oral composition in the oral cavity can be improved by blending a thickener. However, the improvement of the retention property by blending the thickener is usually accompanied by stickiness, and therefore has a drawback that the usability is lowered.
本発明の目的は、液状口腔用組成物において、アラントイン及び/又はその誘導体の安定化、並びに口腔内でのべたつきの抑制及び滞留性の向上を可能にする製剤技術を提供することである。 An object of the present invention is to provide a formulation technique that enables stabilization of allantoin and / or a derivative thereof, suppression of stickiness in the oral cavity, and improvement of retention in a liquid oral composition.
本発明者は、前記課題を解決すべく鋭意検討を行ったところ、アラントイン及び/又はその誘導体、並びに水と共に、ポリビニルピロリドンを含有する液状口腔用組成物は、アラントイン及び/又はその誘導体の安定性が向上しており、優れた保存安定性を備え得ることを見出した。更に、前記液状口腔用組成物は、口腔内でのべたつきが抑制されていながら、滞留性が向上しており、優れた使用感も備え得ることをも見出した。本発明は、これらの知見に基づいて更に検討を重ねることにより完成したものである。 As a result of diligent studies to solve the above problems, the present inventor has found that the liquid oral composition containing polyvinylpyrrolidone together with allantoin and / or its derivative and water has the stability of allantoin and / or its derivative. Has been improved, and it has been found that it can have excellent storage stability. Furthermore, it has also been found that the liquid oral composition has improved retention and can have an excellent usability while suppressing stickiness in the oral cavity. The present invention has been completed by further studies based on these findings.
即ち、本発明は、以下に掲げる態様の発明を提供する。
項1. (A)アラントイン及びその誘導体よりなる群から選択される少なくとも1種、(B)ポリビニルピロリドン及びその誘導体よりなる群から選択される少なくとも1種、並びに(C)水を含有することを特徴とする、液状口腔用組成物。
項2. pHが4〜6である、項1に記載の液状口腔用組成物。
項3. 前記(B)成分の重量平均分子量が5千〜300万である、項1又は2に記載の液状口腔用組成物。
項4. 前記(B)成分の含有量が0.1〜20重量%である、項1〜3のいずれかに記載の液状口腔用組成物。
項5. 前記(A)成分の含有量が0.001〜1重量%である、項1〜4のいずれかに記載の液状口腔用組成物。
項6.更に、クエン酸、及びその塩よりなる群から選択される少なくとも1種を含む、請求項1〜5のいずれかに記載の液状口腔用組成物。
項7. 液体歯磨剤である、項1〜6のいずれかに記載の液状口腔用組成物。
項8. (A)アラントイン及びその誘導体よりなる群から選択される少なくとも1種、並びに(C)水を含有する液状口腔用組成物に、(B)ポリビニルピロリドン及びその誘導体よりなる群から選択される少なくとも1種を配合することを特徴とする、当該液状口腔用組成物中のアラントイン及び/又はその誘導体を安定化する方法。
項9. (A)アラントイン及びその誘導体よりなる群から選択される少なくとも1種、並びに(C)水を含有する液状口腔用組成物に、(B)ポリビニルピロリドン及びその誘導体よりなる群から選択される少なくとも1種を配合することを特徴とする、当該液状口腔用組成物の口腔内での滞留性を向上させる方法。
That is, the present invention provides the inventions of the following aspects.
Item 1. It is characterized by containing (A) at least one selected from the group consisting of allantoin and its derivatives, (B) at least one selected from the group consisting of polyvinylpyrrolidone and its derivatives, and (C) water. , Liquid oral composition.
Item 2. Item 2. The liquid oral composition according to Item 1, which has a pH of 4 to 6.
Item 3. Item 2. The liquid oral composition according to Item 1 or 2, wherein the component (B) has a weight average molecular weight of 50 to 3 million.
Item 4. Item 2. The liquid oral composition according to any one of Items 1 to 3, wherein the content of the component (B) is 0.1 to 20% by weight.
Item 5. Item 2. The liquid oral composition according to any one of Items 1 to 4, wherein the content of the component (A) is 0.001 to 1% by weight.
Item 6. The liquid oral composition according to any one of claims 1 to 5, further comprising at least one selected from the group consisting of citric acid and salts thereof.
Item 7. Item 8. The liquid oral composition according to any one of Items 1 to 6, which is a liquid dentifrice.
Item 8. At least one selected from the group consisting of (A) allantoin and its derivatives, and (C) at least one selected from the group consisting of polyvinylpyrrolidone and its derivatives in a liquid oral composition containing water. A method for stabilizing allantoin and / or a derivative thereof in the liquid oral composition, which comprises blending seeds.
Item 9. At least one selected from the group consisting of (A) allantoin and its derivatives, and (C) at least one selected from the group consisting of polyvinylpyrrolidone and its derivatives in a liquid oral composition containing water. A method for improving the retention of the liquid oral composition in the oral cavity, which comprises blending seeds.
本発明の液状口腔用組成物は、アラントイン及び/又はその誘導体の安定性が向上しており、長期間保存しても、アラントイン及び/又はその誘導体の含有量の低下を抑制し、良好な外観性状を維持させることができる。特に、本発明の液状口腔用組成物は、エタノール等の1価の低級アルコールを配合しなくても、アラントイン及び/又はその誘導体の安定化を図ることができるので、製剤処方の制約が少なく、1価の低級アルコールの刺激を回避し、アルコール過敏症の人の使用に適した製剤処方にすることもできる。 The liquid oral composition of the present invention has improved stability of allantoin and / or its derivative, suppresses a decrease in the content of allantoin and / or its derivative even after long-term storage, and has a good appearance. The properties can be maintained. In particular, the liquid oral composition of the present invention can stabilize allantoin and / or its derivative without blending a monohydric lower alcohol such as ethanol, so that there are few restrictions on formulation. It is also possible to avoid irritation of monovalent lower alcohol and formulate a formulation suitable for use by people with alcohol hypersensitivity.
また、本発明の液状口腔用組成物は、口腔内でのべたつきを抑制しつつ、滞留性を向上できるので、良好な使用感を得ることもできる。 In addition, the liquid oral composition of the present invention can improve the retention while suppressing stickiness in the oral cavity, so that a good usability can be obtained.
1.液状口腔用組成物
本発明の液状口腔用組成物は、アラントイン及びその誘導体よりなる群から選択される少なくとも1種(以下、(A)成分と表記することもある)、ポリビニルピロリドン及びその誘導体よりなる群から選択される少なくとも1種(以下、(B)成分と表記することもある)、並びに水(以下、(C)成分と表記することもある)を含有することを特徴とする。以下、本発明の液状口腔用組成物について詳述する。
1. 1. Liquid Oral Composition The liquid oral composition of the present invention is derived from at least one selected from the group consisting of allantoin and its derivatives (hereinafter, may be referred to as component (A)), polyvinylpyrrolidone and its derivatives. It is characterized by containing at least one selected from the group (hereinafter, may be referred to as component (B)) and water (hereinafter, may be referred to as component (C)). Hereinafter, the liquid oral composition of the present invention will be described in detail.
(A)成分
本発明の液状口腔用組成物は、(A)成分として、アラントイン及びその誘導体よりなる群から選択される少なくとも1種を含有する。アラントイン及び/又はその誘導体には、安定性が劣るという欠点があるが、本発明によれば、後述する(B)成分を配合することによって、水存在下でのアラントイン及び/又はその誘導体の安定性の向上を図りながら、口腔内でのべたつきを抑制しつつ滞留性を向上させることが可能になる。
Component (A) The liquid oral composition of the present invention contains at least one selected from the group consisting of allantoin and its derivatives as the component (A). Allantoin and / or its derivative has a drawback of being inferior in stability, but according to the present invention, by blending the component (B) described later, allantoin and / or its derivative is stable in the presence of water. It is possible to improve the retention while suppressing stickiness in the oral cavity while improving the sexuality.
アラントインは、5−ウレイドヒダントインとも称される化合物であり、抗炎症作用、細胞賦活作用、止血作用、殺菌作用、抗潰瘍作用等を有することが知られている公知の薬剤である。 Allantoin is a compound also called 5-ureidohydantoin, and is a known drug known to have anti-inflammatory action, cell activating action, hemostatic action, bactericidal action, anti-ulcer action and the like.
アラントインの誘導体としては、薬学的に許容できることを限度として特に制限されないが、具体的には、アラントインクロルヒドロキシアルミニウム、アラントインヒドロキシアルミニウム等が挙げられる。これらのアラントインの誘導体は、1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。 The derivative of allantoin is not particularly limited as long as it is pharmaceutically acceptable, and specific examples thereof include allantoin chlorohydroxyaluminum and allantoinhydroxyaluminum. These allantoin derivatives may be used alone or in combination of two or more.
本発明の液状口腔用組成物において、(A)成分として、アラントイン及びその誘導体の中から、1種を選択して使用してもよく、2種以上を組み合わせて使用してもよい。これらの(A)成分の中でも、より一層効果的に安定性を向上させるという観点から、好ましくはアラントインが挙げられる。 In the liquid oral composition of the present invention, as the component (A), one kind may be selected and used from allantoin and its derivatives, or two or more kinds may be used in combination. Among these components (A), allantoin is preferably mentioned from the viewpoint of improving stability even more effectively.
本発明の液状口腔用組成物において、(A)成分の含有量については、当該液状口腔用組成物に備えさせるべき薬効、当該液状口腔用組成物の製剤形態等に応じて適宜設定すればよいが、例えば、0.001〜1重量%、好ましくは0.005〜0.8重量%、更に好ましくは0.01〜0.5重量%が挙げられる。 In the liquid oral composition of the present invention, the content of the component (A) may be appropriately set according to the medicinal effect to be provided in the liquid oral composition, the formulation form of the liquid oral composition, and the like. However, for example, 0.001 to 1% by weight, preferably 0.005 to 0.8% by weight, and more preferably 0.01 to 0.5% by weight can be mentioned.
(B)成分
本発明の液状口腔用組成物は、(B)成分としてポリビニルピロリドン及びその誘導体よりなる群から選択される少なくとも1種を含有する。本発明の液状口腔用組成物において、ポリビニルピロリドン及び/又はその誘導体は、水存在下でのアラントイン及び/又はその誘導体の安定性の向上に寄与すると共に、口腔内でのべたつきを抑制しつつ滞留性を向上させる役割をも果たす。
(B) Component The liquid oral composition of the present invention contains at least one selected from the group consisting of polyvinylpyrrolidone and its derivatives as the component (B). In the liquid oral composition of the present invention, polyvinylpyrrolidone and / or its derivative contributes to the improvement of the stability of allantoin and / or its derivative in the presence of water, and stays while suppressing stickiness in the oral cavity. It also plays a role in improving sex.
ポリビニルピロリドンとは、N−ビニル−2−ピロリドンが重合した水溶性の高分子化合物である。 Polyvinylpyrrolidone is a water-soluble polymer compound in which N-vinyl-2-pyrrolidone is polymerized.
ポリビニルピロリドンの誘導体としては、水溶性を示し、薬学的に許容できることを限度として特に制限されないが、例えば、N−ビニル−2−ピロリドンを構成モノマーとして含む共重合体が挙げられる。ポリビニルピロリドンの誘導体として、具体的には、N−ビニル−2−ピロリドンと、N−ビニル−2−ピロリドンと共重合可能なビニル基を有するビニルモノマーとの共重合体が挙げられる。 Derivatives of polyvinylpyrrolidone are not particularly limited as long as they are water-soluble and pharmaceutically acceptable, and examples thereof include copolymers containing N-vinyl-2-pyrrolidone as a constituent monomer. Specific examples of the derivative of polyvinylpyrrolidone include a copolymer of N-vinyl-2-pyrrolidone and a vinyl monomer having a vinyl group copolymerizable with N-vinyl-2-pyrrolidone.
ポリビニルピロリドンの誘導体において、ビニルピロリドンと共重合させるビニルモノマーとしては、例えば、アクリル酸、メタクリル酸等のエチレン性不飽和カルボン酸及びその塩が挙げられる。ポリビニルピロリドンの誘導体において、これらのビニルモノマーは、1種単独で使用されていてもよく、2種以上を組み合わせて使用されていてもよい。 In the polyvinylpyrrolidone derivative, examples of the vinyl monomer copolymerized with vinylpyrrolidone include ethylenically unsaturated carboxylic acids such as acrylic acid and methacrylic acid and salts thereof. In the derivative of polyvinylpyrrolidone, these vinyl monomers may be used alone or in combination of two or more.
これらのポリビニルピロリドンの誘導体は、1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。 These polyvinylpyrrolidone derivatives may be used alone or in combination of two or more.
本発明の液状口腔用組成物において、(B)成分として、ポリビニルピロリドン及びその誘導体の中から、1種を選択して使用してもよく、2種以上を組み合わせて使用してもよい。これらの(B)成分の中でも、より一層効果的にアラントイン及び/又はその誘導体の安定性の向上、べたつき抑制、並びに滞留性の向上を図るという観点から、好ましくはポリビニルピロリドンが挙げられる。 In the liquid oral composition of the present invention, as the component (B), one kind may be selected and used from polyvinylpyrrolidone and its derivatives, or two or more kinds may be used in combination. Among these components (B), polyvinylpyrrolidone is preferably mentioned from the viewpoint of more effectively improving the stability of allantoin and / or its derivative, suppressing stickiness, and improving the retention.
ポリビニルピロリドン及び/又はその誘導体の重量分子量については、特に制限されないが、より一層効果的にアラントイン及び/又はその誘導体の安定性の向上、べたつき抑制、並びに滞留性の向上を図るという観点から、好ましくは5千〜300万、更に好ましくは4万〜300万が挙げられる。ここで、ポリビニルピロリドン及び/又はその誘導体の重量平均分子量は、ゲルろ過クロマトグラフィー/多角度光散乱光度計(GPC/MALLS)によって測定される値を指す。 The weight molecular weight of polyvinylpyrrolidone and / or its derivative is not particularly limited, but is preferable from the viewpoint of more effectively improving the stability of allantoin and / or its derivative, suppressing stickiness, and improving retention. Is 50 to 3 million, more preferably 40,000 to 3 million. Here, the weight average molecular weight of polyvinylpyrrolidone and / or a derivative thereof refers to a value measured by gel filtration chromatography / multi-angle light scattering photometer (GPC / MALLS).
本発明の液状口腔用組成物において、(B)成分の含有量については、当該液状口腔用組成物の製剤形態等に応じて適宜設定すればよいが、例えば、0.1〜20重量%が挙げられる。特に、より一層効果的にアラントイン及び/又はその誘導体の安定性の向上、べたつき抑制、並びに滞留性の向上を図るという観点から、(B)成分の含有量として、好ましくは0.15〜20重量%、更に好ましくは0.15〜5重量%が挙げられる。 In the liquid oral composition of the present invention, the content of the component (B) may be appropriately set according to the formulation form of the liquid oral composition, and for example, 0.1 to 20% by weight. Can be mentioned. In particular, from the viewpoint of more effectively improving the stability of allantoin and / or its derivative, suppressing stickiness, and improving retention, the content of the component (B) is preferably 0.15 to 20 weight by weight. %, More preferably 0.15 to 5% by weight.
また、本発明の液状口腔用組成物において、(A)成分に対する(B)成分の比率については、前述する(A)成分及び(B)成分の含有量の範囲内を充足し得る範囲であればよいが、具体的には、(A)成分1重量部当たり、(B)成分が通常0.1〜20000重量部、好ましくは0.18〜1000重量部、更に好ましくは0.3〜500重量部が挙げられる。 Further, in the liquid oral composition of the present invention, the ratio of the component (B) to the component (A) should be within the range of the contents of the components (A) and (B) described above. Specifically, the component (B) is usually 0.1 to 20000 parts by weight, preferably 0.18 to 1000 parts by weight, and more preferably 0.3 to 500 parts by weight per 1 part by weight of the component (A). The weight part is mentioned.
(C)成分
本発明の液状口腔用組成物は、(C)成分として水を含有する。アラントイン及び/又はその誘導体は、水との共存下で安定性が低下する傾向を示すが、本発明の液状口腔用組成物によれば、水との共存下で引き起こされるアラントイン及び/又はその誘導体の安定性の低下を効果的に抑制することができる。
(C) component The liquid oral composition of the present invention contains water as the (C) component. Allantoin and / or its derivatives tend to be less stable in the coexistence with water, but according to the liquid oral composition of the present invention, allantoin and / or its derivatives are caused in the coexistence with water. It is possible to effectively suppress the decrease in stability of.
本発明の液状口腔用組成物において、水の含有量については、その製剤形態等に応じて適宜設定されるが、例えば、50〜99.3重量%、好ましくは51〜99.3重量%、更に好ましくは51〜99重量%が挙げられる。 In the liquid oral composition of the present invention, the water content is appropriately set according to the formulation form and the like, and is, for example, 50 to 99.3% by weight, preferably 51 to 99.3% by weight. More preferably, 51 to 99% by weight is mentioned.
1価の低級アルコール
本発明の液状口腔用組成物は、前記(A)〜(C)成分に加えて、必要に応じて1価の低級アルコールが含まれていてもよい。このような1価の低級アルコールとしては、具体的には、エタノール、プロパノール、ブタノール、ペンタノール、ヘキサノール、イソプロパノール等の炭素数1〜6の1価アルコールが挙げられる。これらの1価の低級アルコールは、1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。
Monovalent lower alcohol The liquid oral composition of the present invention may contain a monohydric lower alcohol, if necessary, in addition to the components (A) to (C). Specific examples of such monohydric lower alcohols include monohydric alcohols having 1 to 6 carbon atoms such as ethanol, propanol, butanol, pentanol, hexanol, and isopropanol. These monohydric lower alcohols may be used alone or in combination of two or more.
1価の低級アルコールは、水存在下でのアラントイン及び/又はその誘導体の安定化に寄与できる反面、口腔内で刺激を与える要因になる、アルコール過敏症の人に対しては使用が禁忌となる等の欠点がある。これに対して、本発明の液状口腔用組成物によれば、1価の低級アルコールが少量であったり、含まれていなかったりしても、前記(B)成分によって水存在下でのアラントイン及び/又はその誘導体の安定化を図ることができるので、1価の低級アルコールの前記欠点を低減又は排除することが可能になる。このような本発明の効果を鑑みれば、本発明の液状口腔用組成物における1価の低級アルコールの含有量として、好ましくは10重量%未満、更に好ましくは5重量%未満、より好ましくは1重量%未満が挙げられ、特に、1価の低級アルコールが実質的に含まれていないことが最も好ましい。ここで、1価の低級アルコールが実質的に含まれていないとは、不可避的に混入する微量の1価の低級アルコール以外は、1価の低級アルコールが配合されていないことを意味し、具体的には、1価の低級アルコールが0.1重量%未満であることを指す。 Monovalent lower alcohol can contribute to the stabilization of allantoin and / or its derivatives in the presence of water, but is contraindicated for people with alcohol hypersensitivity, which causes irritation in the oral cavity. There are drawbacks such as. On the other hand, according to the liquid oral composition of the present invention, even if the amount of monohydric lower alcohol is small or not contained, the allantoin and allantoin in the presence of water are produced by the component (B). / Or the derivative thereof can be stabilized, so that the above-mentioned drawbacks of the monohydric lower alcohol can be reduced or eliminated. In view of such effects of the present invention, the content of the monohydric lower alcohol in the liquid oral composition of the present invention is preferably less than 10% by weight, more preferably less than 5% by weight, and more preferably 1% by weight. %, In particular, it is most preferable that the monohydric lower alcohol is substantially not contained. Here, the fact that the monohydric lower alcohol is substantially not contained means that the monohydric lower alcohol is not blended except for a trace amount of the monohydric lower alcohol that is inevitably mixed. Specifically, it means that the monohydric lower alcohol is less than 0.1% by weight.
クエン酸及び/又はその塩
更に、本発明の液状口腔用組成物は、前述する成分に加えて、クエン酸及び/又はその塩が含まれていてもよい。クエン酸及び/又はその塩を含有することにより、水存在下でのアラントイン及び/又はその誘導体の安定化効果を増強させることが可能になる。
Citric acid and / or a salt thereof Further, the liquid oral composition of the present invention may contain citric acid and / or a salt thereof in addition to the above-mentioned components. The inclusion of citric acid and / or a salt thereof makes it possible to enhance the stabilizing effect of allantoin and / or its derivative in the presence of water.
本発明で使用されるクエン酸の塩としては、薬学的に許容されることを限度として、特に制限されないが、ナトリウム塩、カリウム塩等のアルカリ金属塩;カルシウム塩、マグネシウム塩等のアルカリ土類金属塩;アルミニウム塩;アンモニウム塩等が挙げられる。これらのクエン酸の塩は、1種単独で使用してもよく、また2種以上を組わせて使用してもよい。 The salt of citric acid used in the present invention is not particularly limited as long as it is pharmaceutically acceptable, but alkali metal salts such as sodium salt and potassium salt; alkaline earth such as calcium salt and magnesium salt. Examples include metal salts; aluminum salts; ammonium salts and the like. These citric acid salts may be used alone or in combination of two or more.
クエン酸及びその塩の中でも、より一層効果的に水存在下でのアラントイン及び/又はその誘導体の安定化効果を増強させるという観点から、好ましくはクエン酸及びその塩、更に好ましくはクエン酸、クエン酸ナトリウムが挙げられる。 Among citric acid and its salts, preferably citric acid and its salts, more preferably citric acid, citric acid, from the viewpoint of enhancing the stabilizing effect of allantin and / or its derivatives in the presence of water more effectively. Examples include sodium citrate.
本発明の液状口腔用組成物において、クエン酸及び/又はその塩の含有量については、特に制限されないが、例えば、0.05〜2.0重量%、好ましくは0.1〜1.8重量%、更に好ましくは0.1〜1.5重量%が挙げられる。 The content of citric acid and / or a salt thereof in the liquid oral composition of the present invention is not particularly limited, but is, for example, 0.05 to 2.0% by weight, preferably 0.1 to 1.8% by weight. %, More preferably 0.1 to 1.5% by weight.
また、本発明の液状口腔用組成物において、(A)成分に対するクエン酸及び/又はその塩の比率については、前述する(A)成分、並びにクエン酸及び/又はその塩の含有量の範囲内を充足し得る範囲であればよいが、具体的には、(A)成分1重量部当たり、クエン酸及び/又はその塩が通常0.005〜2000重量部、好ましくは0.125〜360重量部、更に好ましくは0.125〜300重量部が挙げられる。 Further, in the liquid oral composition of the present invention, the ratio of citric acid and / or its salt to the component (A) is within the range of the contents of the above-mentioned component (A) and citric acid and / or its salt. However, specifically, citric acid and / or a salt thereof is usually 0.005 to 2000 parts by weight, preferably 0.125 to 360 parts by weight per 1 part by weight of the component (A). Parts, more preferably 0.125 to 300 parts by weight.
その他の成分
本発明の液状口腔用組成物は、前述する成分以外に、本発明の効果を損なわない範囲で、口腔用組成物の製剤形態に応じて、当該技術分野で通常使用される成分を含有していてもよい。このような成分としては、例えば、防腐剤、殺菌剤、抗菌剤、消炎剤、グルコシルトランスフェラーゼ(GTase)阻害剤、プラーク抑制剤、知覚過敏抑制剤、歯石予防剤、歯質強化/再石灰化剤、増粘剤、湿潤剤、賦形剤、香料、甘味剤、清涼化剤、色素、消臭剤、界面活性剤、pH調整剤等が挙げられる。
Other Ingredients In addition to the above-mentioned ingredients, the liquid oral composition of the present invention contains ingredients usually used in the art, depending on the formulation form of the oral composition, as long as the effects of the present invention are not impaired. It may be contained. Such ingredients include, for example, preservatives, bactericides, antibacterial agents, anti-inflammatory agents, glucosyl transferase (GTase) inhibitors, plaque inhibitors, hypersensitivity inhibitors, tartar preventives, dentin strengthening / remineralizing agents. , Thickeners, wetting agents, excipients, fragrances, sweeteners, cooling agents, pigments, deodorants, surfactants, pH adjusters and the like.
防腐剤、殺菌剤、抗菌剤としては、例えば、ヒノキチオール、安息香酸類、サリチル酸類、ソルビン酸類、パラベン類、塩化デカリニウム、塩化ベンゼトニウム、塩化ベンザルコニウム、塩化クロルヘキシジン、グルコン酸クロルヘキシジン、イソプロピルメチルフェノール、トリクロサン、塩化セチルピリジニウム、塩化リゾチーム、塩酸クロルヘキシジン、ヨウ化カリウム等が挙げられる。 Examples of preservatives, bactericides, and antibacterial agents include hinokithiol, benzoic acids, salicylic acids, sorbic acids, parabens, decalinium chloride, benzethonium chloride, benzalkonium chloride, chlorhexidine chloride, chlorhexidine gluconate, isopropylmethylphenol, and triclosan. , Cetylpyridinium chloride, lysoteam chloride, chlorhexidine hydrochloride, potassium iodide and the like.
消炎剤としては、例えば、トラネキサム酸、イプシロンアミノカプロン酸、アズレン、グリチルリチン酸塩、グリチルレチン酸、塩化ナトリウム、ビタミン類等が挙げられる。 Examples of the anti-inflammatory agent include tranexamic acid, epsilon aminocaproic acid, azulene, glycyrrhizinate, glycyrrhetinic acid, sodium chloride, vitamins and the like.
GTase阻害剤としては、例えば、アカバナ科マツヨイグサ属植物の抽出物、ブドウ科ブドウ属植物の抽出物、デキストラナーゼ、ムタナーゼ、タステイン、タンニン類、エラグ酸、ポリフェノール、ウーロン茶抽出物、緑茶抽出物、センブリ、タイソウ、ウイキョウ、芍薬、ゲンチアナ、センソ、龍胆、黄連等が挙げられる。 Examples of GTase inhibitors include extracts of evening primrose plants of the family Evening Primrose, extracts of grapevine plants of the family Grapes, dextranase, mutanase, tastain, tannins, ellagic acid, polyphenols, oolong tea extract, green tea extract, etc. Examples include senburi, evening primrose, tannin, citrus, gentiana, senso, dragon and yellow primrose.
プラーク抑制剤としては、例えばクエン酸亜鉛やグルコン酸等が挙げられる。 Examples of the plaque inhibitor include zinc citrate and gluconic acid.
知覚過敏抑制剤としては、例えば、硝酸カリウム、塩化ストロンチウム等が挙げられる。 Examples of the hypersensitivity inhibitor include potassium nitrate, strontium chloride and the like.
歯石予防剤としては、例えば、ポリリン酸塩類、ゼオライト、エタンヒドロキシジホスフォネート等が挙げられる。 Examples of the tartar preventive agent include polyphosphates, zeolites, ethane hydroxydiphosphonates and the like.
歯質強化/再石灰化剤としては、フッ素、フッ化ナトリウム、フルオロ燐酸ナトリウム、フッ化第一スズ等が挙げられる。 Examples of the dentin strengthening / remineralizing agent include fluorine, sodium fluoride, sodium fluorophosphate, stannous fluoride and the like.
増粘剤としては、例えば、プルラン、プルラン誘導体、デンプン等の多糖類;ヒドロキシプロピルセルロース、ヒドロキシエチルセルロース、ヒドロキシプロピルメチルセルロース、ヒドロキシエチルメチルセルロース、カルボキシメチルセルロース、カルボキシメチルセルロース塩類(カルボキシメチルセルロースナトリウム、カルボキシメチルセルロースカリウム等)、メチルセルロース、エチルセルロース、ポリアクリル酸、ポリアクリル酸塩(ポリアクリル酸ナトリウム、アクリル酸・アクリル酸オクチルエステル共重合体等)、メタアクリル酸類の共重合体(メタアクリル酸とアクリル酸 n−ブチルの重合体、メタアクリル酸とメタアクリル酸メチルの重合体及びメタアクリル酸とアクリル酸エチルの重合体等)等のセルロース系高分子物質;カルボキシビニルポリマー、ポリエチレングリコール、ポリビニルアルコール等の合成高分子物質;レクチン、アルギン酸、アルギン酸塩(アルギン酸ナトリウム、アルギン酸カリウム、アルギン酸マグネシウム、アルギン酸プロピレングリコールエステル、アルギン酸トリエタノールアミン、アルギン酸トリイソプロパノールアミン、アルギン酸アンモニウム、アルギン酸ブチルアミン、アルギン酸ジアミルアミン等)、コンドロイチン硫酸ナトリウム、寒天、キトサン、カラギーナン等の天然系高分子物質;コラーゲン、ゼラチン等のアミノ酸系高分子物質;アラビアガム、カラヤガム、トラガカントガム、キサンタンガム、ローカストビーンガム、グアガム、タマリンドガム、ジェランガム等のゴム系高分子物質等が挙げられる。 Examples of the thickener include polysaccharides such as purulan, purulan derivatives, and starch; hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl methyl cellulose, carboxymethyl cellulose, and carboxymethyl cellulose salts (sodium carboxymethyl cellulose, potassium carboxymethyl cellulose, etc.). , Methyl cellulose, ethyl cellulose, polyacrylic acid, polyacrylic acid salt (sodium polyacrylate, acrylate / acrylate octyl ester copolymer, etc.), copolymer of methacrylic acids (methacrylic acid and n-butyl acrylate) Polymers, polymers of methacrylic acid and methyl methacrylicate, polymers of methacrylic acid and ethyl acrylate, etc.) and other cellulose-based polymer substances; synthetic polymer substances such as carboxyvinyl polymer, polyethylene glycol, polyvinyl alcohol, etc. Lectin, alginic acid, alginate (sodium alginate, potassium alginate, magnesium alginate, propylene glycol alginate, triethanolamine alginate, triisopropanolamine alginate, ammonium alginate, butylamine alginate, diamylamine alginate, etc.), sodium chondroitin sulfate, agar, chitosan , Natural polymer substances such as carrageenan; amino acid polymer substances such as collagen and gelatin; rubber polymer substances such as Arabic gum, Karaya gum, tragacanth gum, xanthan gum, locust bean gum, gua gum, tamarind gum, gellan gum, etc. Be done.
湿潤剤としては、例えば、グリセリン、ソルビトール、エチレングリコール、プロピレングリコール、ポリエチレングリコール、ポリプロピレングリコール、キシリトール、マルチトール、ラクトール、エリスリトール等が挙げられる。 Examples of the wetting agent include glycerin, sorbitol, ethylene glycol, propylene glycol, polyethylene glycol, polypropylene glycol, xylitol, maltitol, lactol, and erythritol.
賦形剤としては、例えば、乳糖、白糖、マンニトール、デンプン、デキストリン、結晶セルロース、シリカ(軽質無水ケイ酸等)等が挙げられる。 Examples of the excipient include lactose, sucrose, mannitol, starch, dextrin, crystalline cellulose, silica (light anhydrous silicic acid, etc.) and the like.
香料としては、例えば、天然香料(ウイキョウ油等)、合成香料、これらの調合香料等が挙げられる。 Examples of the fragrance include natural fragrances (fennel oil and the like), synthetic fragrances, and blended fragrances thereof.
甘味剤としては、サッカリンナトリウム、ステビオサイド、ステビアエキス、アスパルテーム、キシリトール、水飴、蜂蜜、ソルビトール、マルチトール、マンニトール、エリスリトール、糖類(乳糖、白糖、果糖、ブドウ糖等)等が挙げられる。 Examples of the sweetener include sodium saccharin, stebioside, stevia extract, aspartame, xylitol, candy, honey, sorbitol, maltitol, mannitol, erythritol, sugars (lactose, sucrose, fructose, glucose, etc.).
清涼化剤としては、例えば、メントール、メントン、カンフル、ボルネオール、ゲラニオール、これらを含む精油等が挙げられる。 Examples of the refreshing agent include menthol, menthone, camphor, borneol, geraniol, and essential oils containing these.
色素としては、例えば、天然色素、合成色素、これらの混合物が挙げられる。 Examples of the pigment include natural pigments, synthetic pigments, and mixtures thereof.
消臭剤としては、例えば、塩化亜鉛、銅クロロフィリンナトリウム、コーヒー生豆抽出物、ゴボウパウダー、緑茶、焙煎米糠エキス等が挙げられる。 Examples of the deodorant include zinc chloride, sodium copper chlorophyllin, green coffee bean extract, burdock powder, green tea, roasted rice bran extract and the like.
界面活性剤としては、例えば、ポリオキシエチレンラウリルエーテル硫酸ナトリウム、ラウリル硫酸ナトリウム、ミリスチル硫酸ナトリウム、N−ラウロイルサルコシン酸ナトリウム、N−ミリストリルサルコシン酸ナトリウム、ドデシルベンゼンスルホン酸ナトリウム、水素添加ココナッツ脂肪酸モノグリセリドモノ硫酸ナトリウム、ラウリルスルホ酢酸ナトリウム、α−オレフィンスルホン酸ナトリウム、N−パルミトイルグルタルミン酸ナトリウム、N−メチル−N−アシルタウリンナトリウム等の陰イオン性界面活性剤;ポリオキシエチレン硬化ヒマシ油、ショ糖脂肪酸エステル、マルトース脂肪酸エステル、マルチトール脂肪酸エステル、ラクトール脂肪酸エステル、ソルビタン脂肪酸エステル、ポリオキシエチレンソルビタンモノステアレート、ポリオキシエチレン高級アルコールエーテル、ポリオキシエチレンポリオキシプロピレン共重合体、ポリオキシエチレンポリオキシプロピレン脂肪酸エステル、ポリグリセリン脂肪酸エステル等の非イオン性界面活性剤;ヤシ油脂肪酸アミドプロピルベタイン、ラウリルジメチルアミノ酢酸ベタイン、ラウリルジメチルアミンオキシド、2-アルキル−N−カルボキシメチル−N−ヒドロキシエチルイミダゾリウムベタイン、N−ラウリルジアミノエチルグリシン、N−ミリスチルジアミノエチルグリシン、N−アルキル−1−ヒドロキシエチルイミダゾリンベタインナトリウム等の両性界面活性剤;塩化ラウリルトリメチルアンモニウム、塩化ステアリルトリメチルアンモニウム、塩化ベンゼトニウム、塩化ベンザルコニウム、塩化ステアリルジメチルベンジルアンモニウム等の陽イオン性界面活性剤が挙げられる。 Examples of the surfactant include polyoxyethylene lauryl ether sulfate, sodium lauryl sulfate, sodium myristyl sulfate, sodium N-lauroyl sarcosinate, sodium N-myristolyl sarcosinate, sodium dodecylbenzene sulfonate, hydrogenated coconut fatty acid monoglyceride. Anionic surfactants such as sodium monosulfate, sodium lauryl sulfoacetate, sodium α-olefin sulfonate, sodium N-palmitoyl glutarmate, sodium N-methyl-N-acyl taurine; polyoxyethylene hydrogenated castor oil, sho Sugar fatty acid ester, maltose fatty acid ester, maltol fatty acid ester, lactol fatty acid ester, sorbitan fatty acid ester, polyoxyethylene sorbitan monostearate, polyoxyethylene higher alcohol ether, polyoxyethylene polyoxypropylene copolymer, polyoxyethylene poly Nonionic surfactants such as oxypropylene fatty acid ester and polyglycerin fatty acid ester; coconut oil fatty acid amide propyl betaine, lauryl dimethylamino acetate betaine, lauryl dimethyl amine oxide, 2-alkyl-N-carboxymethyl-N-hydroxyethyl imidazole Amphoteric surfactants such as lumbetaine, N-lauryl diaminoethyl glycine, N-myristyl diaminoethyl glycine, N-alkyl-1-hydroxyethyl imidazoline betaine sodium; lauryl trimethyl ammonium chloride, stearyl trimethyl ammonium chloride, benzethonium chloride, benza chloride Examples thereof include cationic surfactants such as luconium and stearyldimethylbenzylammonium chloride.
pH調整剤としては、例えば、酢酸、塩酸、硫酸、硝酸、クエン酸、リン酸、水酸化ナトリウム、水酸化カリウム、酢酸ナトリウム、炭酸ナトリウム、クエン酸ナトリウム、クエン酸水素ナトリウム、リン酸ナトリウム、リン酸水素ナトリウム等が挙げられる。 Examples of the pH adjuster include acetic acid, hydrochloric acid, sulfuric acid, nitric acid, citric acid, phosphoric acid, sodium hydroxide, potassium hydroxide, sodium acetate, sodium carbonate, sodium citrate, sodium hydrogen citrate, sodium phosphate, and phosphorus. Examples thereof include sodium hydrogen acid.
pH及び粘度
本発明の液状口腔用組成物の粘度については、特に制限されないが、例えば、25℃での粘度として、5〜100mPa・Sが挙げられる。より一層効果的べたつき抑制及び滞留性の向上を図るという観点から本発明の液状口腔用組成物の25℃での粘度として、好ましくは7〜70mPa・S、更に好ましくは18〜40mPa・Sが挙げられる。ここで、25℃での粘度とは、B型回転粘度計(スピンドル:LVスピンドルNo.2、回転数60rpm)にて測定される25℃での粘度を意味する。
pH and Viscosity The viscosity of the liquid oral composition of the present invention is not particularly limited, and examples thereof include 5 to 100 mPa · S as the viscosity at 25 ° C. From the viewpoint of more effectively suppressing stickiness and improving retention, the viscosity of the liquid oral composition of the present invention at 25 ° C. is preferably 7 to 70 mPa · S, more preferably 18 to 40 mPa · S. Be done. Here, the viscosity at 25 ° C. means the viscosity at 25 ° C. measured by a B-type rotational viscometer (spindle: LV spindle No. 2, rotation speed 60 rpm).
本発明の液状口腔用組成物は、前記(B)成分を前述する含有量で配合させることによって前記粘度を備えさせ得るが、粘度を調整するために、必要に応じて、前記(B)成分以外に前記粘着剤や粘稠剤を適宜配合してもよい。 The liquid oral composition of the present invention may be provided with the viscosity by blending the component (B) in the above-mentioned content, but in order to adjust the viscosity, the component (B) is required. In addition to this, the pressure-sensitive adhesive and the viscous agent may be appropriately added.
また、本発明の液状口腔用組成物のpHについては、口腔内への適用が許容される範囲で適宜設定すればよいが、アラントイン及び/又はその誘導体の安定性をより一層向上させるという観点から、通常4〜6、好ましくは4〜5.6、更に好ましくは4〜5.3が挙げられる。ここで、pHとは、25℃の温度条件下で測定される値である。 Further, the pH of the liquid oral composition of the present invention may be appropriately set within a range where application to the oral cavity is permitted, but from the viewpoint of further improving the stability of allantoin and / or its derivative. , Usually 4 to 6, preferably 4 to 5.6, and more preferably 4 to 5.3. Here, the pH is a value measured under a temperature condition of 25 ° C.
本発明の液状口腔用組成物のpHは、前述するpH調整剤を配合することによって調整することができる。 The pH of the liquid oral composition of the present invention can be adjusted by adding the above-mentioned pH adjuster.
製剤形態
本発明の液状口腔用組成物の製剤形態は、液状であり、口腔内に適用されて口腔内で一定時間滞留し得るものである限り制限されないが、例えば、液体歯磨剤、液状歯磨剤、洗口液(液体歯磨剤、洗口液は、一般にマウスリンス、マウスウォッシュ、デンタルリンス等と呼称されることがある)、口中清涼剤(マウススプレー等)等の口腔衛生剤が挙げられる。これらの中でも、好ましくは液体歯磨剤、液状歯磨剤、洗口液、更に好ましくは液体歯磨剤、洗口液が挙げられる。
Formulation form The formulation form of the liquid oral composition of the present invention is not limited as long as it is liquid and can be applied to the oral cavity and stay in the oral cavity for a certain period of time. For example, a liquid dentifrice or a liquid dentifrice. , Mouthwash (liquid dentifrice, mouthwash may be generally called mouth rinse, mouth wash, dental rinse, etc.), oral hygiene agent such as mouth refreshing agent (mouth spray, etc.). Among these, a liquid dentifrice, a liquid dentifrice, and a mouthwash are preferable, and a liquid dentifrice and a mouthwash are more preferable.
2.アラントイン及び/又はその誘導体の安定化方法、及び安定化剤
前述するように、アラントイン及び/又はその誘導体と水とを含む液状口腔用組成物に、ポリビニルピロリドン及び/又はその誘導体を配合することによって、当該液状口腔用組成物中のアラントイン及び/又はその誘導体を安定化させ、保存安定性を向上させることができる。
2. 2. Stabilizing method and stabilizer of allantoin and / or its derivative As described above, by blending polyvinylpyrrolidone and / or its derivative in a liquid oral composition containing allantoin and / or its derivative and water. , Allantoin and / or its derivative in the liquid oral composition can be stabilized and storage stability can be improved.
従って、本発明は、更に、(A)アラントイン及びその誘導体よりなる群から選択される少なくとも1種、並びに(C)水を含有する液状口腔用組成物に、(B)ポリビニルピロリドン及びその誘導体よりなる群から選択される少なくとも1種を配合することを特徴とする、当該液状口腔用組成物中のアラントイン及び/又はその誘導体を安定化する方法(安定化方法)を提供する。 Therefore, the present invention further comprises (B) polyvinylpyrrolidone and its derivatives in a liquid oral composition containing (A) at least one selected from the group consisting of allantoin and its derivatives, and (C) water. Provided is a method (stabilization method) for stabilizing allantoin and / or a derivative thereof in the liquid oral composition, which comprises blending at least one selected from the above group.
また、本発明は、(A)アラントイン及びその誘導体よりなる群から選択される少なくとも1種、並びに(C)水を含有する液状口腔用組成物において、アラントイン及び/又はその誘導体を安定化させるために使用される安定化剤であって、(B)ポリビニルピロリドン及びその誘導体よりなる群から選択される少なくとも1種を有効成分とすることを特徴とする、安定化剤を提供する。 Further, the present invention is intended to stabilize allantoin and / or its derivative in a liquid oral composition containing (A) at least one selected from the group consisting of allantoin and its derivative, and (C) water. Provided is a stabilizer used in (B), which comprises at least one selected from the group consisting of polyvinylpyrrolidone and its derivatives as an active ingredient.
本発明の安定化方法及び安定化剤に使用される成分の種類や添加量、適用対象となる液状口腔用組成物等については、前記「1.液状口腔用組成物」に記載の通りである。 The type and amount of the components used in the stabilizing method and stabilizer of the present invention, the liquid oral composition to be applied, and the like are as described in "1. Liquid oral composition" above. ..
3.液状口腔用組成物の口腔内での滞留性向上方法、及び口腔内滞留性向上剤
前述するように、アラントイン及び/又はその誘導体と水とを含む液状口腔用組成物に、ポリビニルピロリドン及び/又はその誘導体を配合することによって、当該液状口腔用組成物の口腔内での滞留性を向上させることができる。
3. 3. A method for improving the retention of a liquid oral composition in the oral cavity and an agent for improving the retention in the oral cavity As described above, polyvinylpyrrolidone and / or a liquid oral composition containing allantin and / or a derivative thereof and water. By blending the derivative, the retention of the liquid oral composition in the oral cavity can be improved.
従って、本発明は、更に、(A)アラントイン及びその誘導体よりなる群から選択される少なくとも1種、並びに(C)水を含有する液状口腔用組成物に、(B)ポリビニルピロリドン及びその誘導体よりなる群から選択される少なくとも1種を配合することを特徴とする、当該液状口腔用組成物の口腔内での滞留性を向上させる方法(滞留性向上方法)を提供する。 Therefore, the present invention further comprises (B) polyvinylpyrrolidone and its derivatives in a liquid oral composition containing (A) at least one selected from the group consisting of allantoin and its derivatives, and (C) water. Provided is a method for improving the retention of the liquid oral composition in the oral cavity (method for improving retention), which comprises blending at least one selected from the above group.
また、本発明は、(A)アラントイン及びその誘導体よりなる群から選択される少なくとも1種、並びに(C)水を含有する液状口腔用組成物の口腔内での滞留性を向上させるために使用される口腔内滞留性向上剤であって、(B)ポリビニルピロリドン及びその誘導体よりなる群から選択される少なくとも1種を有効成分とすることを特徴とする口腔内滞留性向上剤を提供する。 The present invention is also used to improve the retention of a liquid oral composition containing (A) at least one selected from the group consisting of allantin and its derivatives, and (C) water in the oral cavity. Provided is an oral retention improver, which comprises at least one selected from the group consisting of (B) polyvinylpyrrolidone and its derivatives as an active ingredient.
本発明の滞留性向上方法及び口腔内滞留性向上剤に使用される成分の種類や添加量、適用対象となる液状口腔用組成物等については、前記「1.液状口腔用組成物」に記載の通りである。 The type and amount of the component used in the retention improving method and the oral retention improving agent of the present invention, the liquid oral composition to be applied, and the like are described in the above "1. Liquid oral composition". It is a street.
以下に、実施例等に基づいて本発明を詳細に説明するが、本発明はこれらによって限定されるものではない。 Hereinafter, the present invention will be described in detail based on Examples and the like, but the present invention is not limited thereto.
試験例
1.試験方法
表1及び2に示す組成の液体歯磨剤(実施例1〜16及び比較例1〜7)を調製し、以下に示す方法で、pH、粘度、使用感(口腔内での滞留性及びべたつき)、保存後のアラントインの安定性及び外観性状について評価を行った。
Test example
1. 1. Test method Liquid dentifrices (Examples 1 to 16 and Comparative Examples 1 to 7) having the compositions shown in Tables 1 and 2 were prepared, and the pH, viscosity, and usability (retention in the oral cavity and oral retention and oral stability) were prepared by the methods shown below. The stability and appearance of allantoin after storage were evaluated.
1−1.pHの測定
25℃の各液体歯磨剤のpHについて、pHメーター(型式:F−53、株式会社堀場製作所製)を用いて測定した。
1-1. Measurement of pH The pH of each liquid dentifrice at 25 ° C. was measured using a pH meter (model: F-53, manufactured by HORIBA, Ltd.).
1−2.粘度の測定
各液体歯磨剤の粘度について、B型回転粘度計(機種:LVT、ブルックフィールド社製)を用いて、下記の条件で測定した。
スピンドル:LVスピンドルNo.2
回転速度:60rpm
LVスピンドルフィルター:5
測定時間:回転開始から30秒経過後
測定温度:25℃
1-2. Viscosity measurement The viscosity of each liquid dentifrice was measured using a B-type rotational viscometer (model: LVT, manufactured by Brookfield) under the following conditions.
Spindle: LV Spindle No. 2
Rotation speed: 60 rpm
LV spindle filter: 5
Measurement time: 30 seconds after the start of rotation Measurement temperature: 25 ° C
1−3.使用感(口腔内での滞留性及びべたつき)の評価
各液体歯磨剤10mlを口に含み、30秒間、口をすすいで吐出した後に、以下の方法で口腔内での滞留性及びべたつきを評価した。なお、本試験は、5名のパネラーによって行った。
(口腔内での滞留性)
以下の判定基準に従って、口腔内での滞留性を評点化した。
判定基準
3点:液体歯磨剤を吐出した後に、液体歯磨剤の残留性を十分に感じる。
2点:液体歯磨剤を吐出した後に、液体歯磨剤の残留性を感じる。
1点:液体歯磨剤を吐出した後に、液体歯磨剤の残留性を僅かに感じる。
0点:液体歯磨剤を吐出した後に、液体歯磨剤の残留性を感じない。
1-3. Evaluation of usability (retention and stickiness in the oral cavity) After containing 10 ml of each liquid dentifrice in the mouth and rinsing the mouth for 30 seconds, the retention and stickiness in the oral cavity were evaluated by the following method. .. This test was conducted by 5 panelists.
(Staying in the oral cavity)
The retention in the oral cavity was scored according to the following criteria.
Judgment criteria 3 points: After discharging the liquid dentifrice, the residual property of the liquid dentifrice is sufficiently felt.
2 points: After discharging the liquid dentifrice, the residual liquid dentifrice is felt.
1 point: After discharging the liquid dentifrice, the residual liquid dentifrice is slightly felt.
0 point: No residual liquid dentifrice is felt after discharging the liquid dentifrice.
次いで、各液体歯磨剤について、5名のパネラーによる評点の合計点を算出し、以下の評価分類に従って、口腔内での滞留性を評価した。
評価分類
◎:評点の合計点が12〜15点
○:評点の合計点が9〜11点
△:評点の合計点が6〜8点
×:評点の合計点が0〜5点
Next, for each liquid dentifrice, the total score of the scores by the five panelists was calculated, and the retention in the oral cavity was evaluated according to the following evaluation classification.
Evaluation classification ◎: Total score is 12 to 15 points ○: Total score is 9 to 11 points △: Total score is 6 to 8 points ×: Total score is 0 to 5 points
(べたつき)
液体歯磨剤を吐出した後に、「口腔内にべたつきを感じる」を0点、「口腔内にべたつきを感じない」を10点として、VAS(visual analogue Scale)法にて評点化した。次いで、各洗口剤について、5名のパネラーによる評点の平均値を算出し、以下の評価分類に従って、べたつきについて評価した。
評価分類
◎:評点の平均点が9〜10点
○:評点の平均点が7〜8点
△:評点の平均点が3〜6点
×:評点の平均点が0〜2点
(Sticky)
After the liquid dentifrice was discharged, "feeling stickiness in the oral cavity" was given as 0 point, and "not feeling sticky in the oral cavity" was given as 10 points, which were scored by the VAS (visual analog scale) method. Next, for each mouthwash, the average value of the scores by the five panelists was calculated, and the stickiness was evaluated according to the following evaluation classification.
Evaluation classification ◎: Average score is 9 to 10 points ○: Average score is 7 to 8 points △: Average score is 3 to 6 points ×: Average score is 0 to 2 points
1−5.保存後のアラントインの安定性及び外観性状の評価
各液体歯磨剤60mlを80ml容のガラス容器に充填し、蓋をして密封し、60℃の暗所で2週間保存した。
1-5. Evaluation of stability and appearance of allantoin after storage 60 ml of each liquid dentifrice was filled in a glass container containing 80 ml, covered and sealed, and stored in a dark place at 60 ° C. for 2 weeks.
保存前後の各液体歯磨剤に含まれるアラントインの含有量を高速液体クロマトグラフィーにて測定し、保存前のアラントインの含有量を100%として、以下の評価分類に従って、アラントインの安定性を評価した。
評価分類
◎:保存後に残存しているアラントインが95%以上である。
○:保存後に残存しているアラントインが91%以上95%未満である。
△:保存後に残存しているアラントインが90%以上91%未満である。
×:保存後に残存しているアラントインが88%以上90%未満である。
××:保存後に残存しているアラントインが88未満である。
The content of allantoin contained in each liquid dentifrice before and after storage was measured by high performance liquid chromatography, and the stability of allantoin was evaluated according to the following evaluation classification, assuming that the content of allantoin before storage was 100%.
Evaluation classification ⊚: Allantoin remaining after storage is 95% or more.
◯: Allantoin remaining after storage is 91% or more and less than 95%.
Δ: The amount of allantoin remaining after storage is 90% or more and less than 91%.
X: The amount of allantoin remaining after storage is 88% or more and less than 90%.
XX: The amount of allantoin remaining after storage is less than 88.
また、保存後の各液体歯磨剤の外観を観察し、以下の評価分類に従って、外観性状を評価した。
評価分類
◎:成分の析出や濁りが全く認められず、澄明である。
△:成分の析出や濁りが僅かに認められる。
×:成分の析出と濁りが明らかに認められる。
In addition, the appearance of each liquid dentifrice after storage was observed, and the appearance properties were evaluated according to the following evaluation classification.
Evaluation classification ⊚: It is clear with no precipitation or turbidity of the components.
Δ: Slight precipitation and turbidity of the components are observed.
X: Precipitation and turbidity of the components are clearly observed.
2.試験結果
得られた結果を表1及び2に示す。表1から明らかなように、アラントイン、ポリビニルピロリドン、及び水を含む液体歯磨剤では、60℃で2週間保存した後でも、アラントインが安定に維持され、良好な外観性状を備えていた(実施例1〜15)。特に、アラントイン、ポリビニルピロリドン、及び水を含む場合には、エタノールを含んでいなくても、アラントインを安定化できていた。
2. 2. Test Results The results obtained are shown in Tables 1 and 2. As is clear from Table 1, in the liquid dentifrice containing allantoin, polyvinylpyrrolidone, and water, allantoin was stably maintained and had good appearance properties even after storage at 60 ° C. for 2 weeks (Example). 1 to 15). In particular, when allantoin, polyvinylpyrrolidone, and water were contained, allantoin could be stabilized even if ethanol was not contained.
一方、ポリビニルピロリドン以外の増粘剤を含む場合には、アラントインが経時的に分解し、初期に比して90%を割るとの結果となり、十分な有効性を発揮できる組成物ではなくなっていた(比較例1〜6)。また、比較例1〜6では、外観性状についても安定に保つことができなくなっており、更に口腔内での滞留性やべたつきの面でも使用者の満足に耐えるのものではなかった。 On the other hand, when a thickener other than polyvinylpyrrolidone was contained, allantoin decomposed over time, resulting in less than 90% of the initial composition, and the composition was no longer capable of exhibiting sufficient effectiveness. (Comparative Examples 1 to 6). Further, in Comparative Examples 1 to 6, the appearance properties could not be kept stable, and the retention in the oral cavity and the stickiness were not satisfied by the user.
製造例:液体歯磨剤(洗口液)
表3〜5に記載の組成の液体歯磨剤(洗口液)を調製した。得られた各液体歯磨剤(洗口液)について、前記試験例と同様の方法で、使用感(口腔内での滞留性、べたつき)、60℃2週間保存後のアラントインの安定性と外観性状を評価したところ、いずれも良好であった。
Production example: Liquid dentifrice (mouthwash)
Liquid dentifrices (mouthwashes) having the compositions shown in Tables 3 to 5 were prepared. For each of the obtained liquid dentifrices (mouthwash), the feeling of use (retention in the oral cavity, stickiness), stability and appearance of allantoin after storage at 60 ° C for 2 weeks were carried out in the same manner as in the above test example. As a result of evaluation, all were good.
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015064356A JP6832616B2 (en) | 2015-03-26 | 2015-03-26 | Liquid oral composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015064356A JP6832616B2 (en) | 2015-03-26 | 2015-03-26 | Liquid oral composition |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016183128A JP2016183128A (en) | 2016-10-20 |
JP6832616B2 true JP6832616B2 (en) | 2021-02-24 |
Family
ID=57242491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015064356A Active JP6832616B2 (en) | 2015-03-26 | 2015-03-26 | Liquid oral composition |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6832616B2 (en) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5951539B2 (en) * | 1976-01-08 | 1984-12-14 | 川研フアインケミカル株式会社 | Novel allantoin-N-acetylglutamine-aluminum molecular compound and method for producing the same |
US4117141A (en) * | 1977-02-18 | 1978-09-26 | Dov Michaeli | Method of inhibiting flea-bite allergy |
JPS6036463A (en) * | 1983-08-08 | 1985-02-25 | Grelan Pharmaceut Co Ltd | Allantoin derivative |
JP3473036B2 (en) * | 1992-12-18 | 2003-12-02 | 帝國製薬株式会社 | Aldioxa-containing aqueous preparation |
JP2006182699A (en) * | 2004-12-27 | 2006-07-13 | Lion Corp | Composition for oral cavity |
CN102198126B (en) * | 2011-05-04 | 2012-11-28 | 刘布鸣 | Liniment for treating mouth and tooth diseases and applicator |
JP5683389B2 (en) * | 2011-06-13 | 2015-03-11 | 花王株式会社 | Transparent liquid oral composition |
-
2015
- 2015-03-26 JP JP2015064356A patent/JP6832616B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2016183128A (en) | 2016-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2009343761B2 (en) | Dentifrice composition | |
JP7011407B2 (en) | Oral composition | |
JP2019052110A (en) | Oral composition | |
JP6381912B2 (en) | Oral composition | |
JP6513360B2 (en) | Oral composition | |
JP7108383B2 (en) | oral composition | |
JP7455317B2 (en) | Oral composition | |
JP6968523B2 (en) | Oral or external composition | |
JP7193788B2 (en) | Inhibitor of invasion of periodontal bacteria into gingival tissue cells | |
JP2019112375A (en) | Oral composition | |
JP2021095380A (en) | Dentifrice composition | |
JP6734090B2 (en) | Oral composition | |
JP6832616B2 (en) | Liquid oral composition | |
JP6946075B2 (en) | Oral composition | |
JP7000048B2 (en) | Oral composition | |
JP7442257B2 (en) | Tooth stain adhesion inhibitor | |
JP7594347B2 (en) | Oral Composition | |
JP7050135B2 (en) | Oral or external composition | |
JP7602855B2 (en) | Agents for inhibiting the destruction of gingival tissue | |
JP6925929B2 (en) | Oral composition | |
JP2004051535A (en) | Composition for oral cavity | |
JP7594346B2 (en) | Oral Composition | |
JP7048272B2 (en) | Oral composition | |
JP6349709B2 (en) | Oral composition | |
JP7594345B2 (en) | Oral Composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180221 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181120 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190117 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190318 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190528 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20190828 |
|
C116 | Written invitation by the chief administrative judge to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C116 Effective date: 20190910 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20190910 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20200609 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20200804 |
|
C13 | Notice of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: C13 Effective date: 20200901 |
|
C28A | Non-patent document cited |
Free format text: JAPANESE INTERMEDIATE CODE: C2838 Effective date: 20200901 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201030 |
|
C23 | Notice of termination of proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C23 Effective date: 20201124 |
|
C03 | Trial/appeal decision taken |
Free format text: JAPANESE INTERMEDIATE CODE: C03 Effective date: 20210105 |
|
C30A | Notification sent |
Free format text: JAPANESE INTERMEDIATE CODE: C3012 Effective date: 20210105 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210202 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6832616 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |